Baltimore, MD, USA
Emergent BioSolutions (acquirer of Cangene bioPharma) provides contract manufacturing services for both bulk drug substances and finished drug products. Emergent's state-of-the-art single-use BDS facility enables turnkey upstream and downstream support for microbial, mammalian and viral cell lines. Emergent's Fill/Finish service offering includes vials and syringes, for both liquid and lyophilized products (including lyo cycle development). Emergent's manufacturing facilities (located in Baltimore, MD) currently produce 20 commercial products and supported over 200 clinical drug products.
Emergent BioSolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Emergent BioSolutions on the Pharma Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
